INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jul 23, 2026

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.

PRNewsWire • Jul 23, 2026

Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 22, 2026

Ionis Pharmaceuticals: The Heartbreak Is Priced In

The ATTR-CM and tominersen setbacks drove an excessive selloff without impairing Ionis's wholly owned core assets. Tryngolza is the main value driver, supported by strong triglyceride and pancreatitis data and a large sHTG market. Dawnzera's upcoming pipeline catalysts and $1.9B of liquidity support growth and a credible path to 2028 breakeven.

Seeking Alpha • Jul 16, 2026

Ionis to hold second quarter 2026 financial results webcast

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented me.

Business Wire • Jul 15, 2026

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.

GlobeNewsWire • Jul 15, 2026

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

Zacks Investment Research • Jul 15, 2026

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical effi.

Business Wire • Jul 14, 2026

Levi & Korsinsky Notifies Investors of a Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (NASDAQ: IONS) investors absorbed a >20% share decline after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint. Levi & Korsinsky is investigating potential securities law violations.

GlobeNewsWire • Jul 14, 2026

Ionis Begins Dosing in Phase I/II Dravet Syndrome Study

IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.

Zacks Investment Research • Jul 14, 2026